This trial has been completed.

Condition hemophilia a
Sponsor CancerCare Manitoba
Collaborator The Hospital for Sick Children
Start date September 2014
End date December 2015
Trial size 42 participants
Trial identifier NCT02225483, H2013:304


The is study will examine whether variation in clinical bleeding frequency and severity among boys with severe Hemophilia A (Factor VIII deficiency) is associated with variations in laboratory measurements of platelet activity.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-control
Time perspective prospective
Boys with Factor VIII coagulant activity less than or equal to 1%.

Primary Outcomes

Procoagulant platelet-derived microparticle formation
time frame: At time of enrollment
Platelet aggregation
time frame: At time of enrollment

Eligibility Criteria

Male participants from 3 years up to 20 years old.

Inclusion Criteria: - documented circulating FVIII level of ≤1% - age 3 - 20 years - may be on primary or secondary prophylaxis - granting of informed consent Exclusion Criteria: - measurable inhibitor level at the time of enrollment - ingestion of aspirin/supplement known to influence platelet function within 14 days of blood sampling, or ibuprofen within 3 days

Additional Information

Official title Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by CancerCare Manitoba.